恒瑞医药: 恒瑞医药第九届董事会第十四次会议决议公告

Core Points - The board of directors of Jiangsu Hengrui Medicine Co., Ltd. held its 14th meeting of the 9th session on April 2, 2025, and all 9 directors were present, confirming compliance with the Company Law and Articles of Association [1][2]. Group 1: Board Elections - The board elected Mr. Dai Hongbin as the vice chairman and Ms. Feng Ji as a director, with terms lasting until the current board's term ends [1][2]. - Mr. Dai Hongbin has been with the company since July 2000, holding various positions including General Manager since May 2022 [1]. - Ms. Feng Ji has over 30 years of experience in various management roles, including significant positions at AstraZeneca and has been appointed as the General Manager (CEO) and Chief Operating Officer [2][3]. Group 2: Resolutions Passed - The election of the vice chairman and director received 8 votes in favor, with no opposition or abstentions [2]. - The proposal to appoint Ms. Feng Ji as General Manager (CEO) was unanimously approved with 9 votes in favor [3]. - Amendments to the Articles of Association and the proposal to convene the 2024 annual shareholders' meeting will be submitted for approval at the upcoming shareholders' meeting [3].